drugset / Trial / NCT04728971
To Evaluate the Efficacy and Safety of Micafungin in Preventing Invasive Mycosis After Liver Transplantation
Phase 4
Unknown
200 enrolled
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Non-randomizedSingle-groupOpen-labelPrevention
Summary
To evaluate the clinical success rate of micafungin in preventing invasive mycosis after liver transplantation.
Timeline
- Start
- 2022-10-01
- Primary completion
- 2025-10-01
- Completion
- 2026-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Caspofungin | Other / unclassified | 35 mg | — |
| Subject | Micafungin | Peptide | 150 mg | — |
Indications
No indication recorded.